395683-14-4
395683-14-4
Chemical Structure
Imrecoxib
Synonym(s): BAP-909
- CAS No.: 395683-14-4
- Formula:C21H23NO3S
- Molecular Weight:369.48
IUPAC Name: 4-(4-(methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1,5-dihydro-2H-pyrrol-2-one
InChIKey: AXMZZGKKZDJGAZ-UHFFFAOYSA-N
SMILES: O=C1N(CCC)CC(C2=CC=C(S(=O)(C)=O)C=C2)=C1C3=CC=C(C)C=C3
Biological Activity: Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Imrecoxib | 99.48% | Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imrecoxib (Standard) | ≥98% | Imrecoxib (Standard) is the analytical standard of Imrecoxib. This product is intended for research and analytical applications. Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imrecoxib-d7 | Imrecoxib-d7 (BAP-909-d7) is the deuterium labeled Imrecoxib (HY-114200). Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DRF-4848 | DRF-4848 is a COX-2 inhibitor. DRF-4848 can be used for the research of inflammation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4'-Aarboxylic acid imrecoxib | 99.29% | 4'-Aarboxylic acid imrecoxib is a metabolite of Imrecoxib, a selective COX-II inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rofecoxib (Standard) | ≥98% | Rofecoxib (Standard) is the analytical standard of Rofecoxib. This product is intended for research and analytical applications. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rofecoxib-d5 | Rofecoxib-d5 is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
APD-916 | APD-916 is an H3 receptor antagonist. APD-916 shows good pharmacokinetic properties, and oral administration of APD-916 has been shown to enhance wakefulness in various animal models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycolic acid oxidase inhibitor 1 | 99.35% | Glycolic acid oxidase inhibitor 1 is a glycolate oxidase inhibitor, extracted from patent EP0021228A1, in Table IV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2,2,2-Trifluoro-1-(4'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)ethanone | 99.41% | 2,2,2-Trifluoro-1-(4'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)ethanone (Odanacatib intermediate) is a drug intermediate for synthesis of various active compounds. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulindac sulfone | 98.10% | Sulindac sulfone is an orally active metabolite of Sulindac (HY-B0008). Sulindac sulfone activates PPARγ and drives transcriptional induction of SSAT by binding to the PPRE-2 element. Sulindac sulfone induces Apoptosis. Sulindac sulfone negatively regulates the function of VDAC1/2 to inhibit the mTORC1 pathway, reduces Cyclin D1 levels, and induces G1 cell cycle arrest in colon cancer cells. Sulindac sulfone exerts colon cancer preventive effects through a COX-independent mechanism. Sulindac sulfone can be used in research related to colon cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SC57666 | 98.94% | SC57666 is a selective COX2 inhibitor with an IC50 of 26 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SC58451 | SC58451 is a potent and selective Cox-2 inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
